RCKT insider disclosures
Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source | Follow |
|---|---|---|---|---|---|---|---|
| Shah Gaurav CEO · ROCKET PHARMACEUTICALS, INC. | RCKT ROCKET PHARMACEUTICALS, INC. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 1051358 · SEC code covers open-market or private transactions · Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. · The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. | 2026-11-18 | 2026-11-20 | ≈ $4,826.45 2,216 shares/units | SEC 4 | Follow |
| Wilson Martin General Counsel · ROCKET PHARMACEUTICALS, INC. | RCKT ROCKET PHARMACEUTICALS, INC. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 540336 · SEC code covers open-market or private transactions · Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. · The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. | 2026-11-18 | 2026-11-20 | ≈ $1,474.51 677 shares/units | SEC 4 | Follow |
| Shah Gaurav CEO · ROCKET PHARMACEUTICALS, INC. | RCKT ROCKET PHARMACEUTICALS, INC. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 1053574 · SEC code covers open-market or private transactions · Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. · The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. | 2026-11-13 | 2026-11-17 | ≈ $6,795.00 3,020 shares/units | SEC 4 | Follow |
| Wilson Martin General Counsel · ROCKET PHARMACEUTICALS, INC. | RCKT ROCKET PHARMACEUTICALS, INC. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 541013 · SEC code covers open-market or private transactions · Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. · The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. | 2026-11-13 | 2026-11-17 | ≈ $9,195.75 4,087 shares/units | SEC 4 | Follow |
| Chaudhuri Sarbani See Remarks · ROCKET PHARMACEUTICALS, INC. | RCKT ROCKET PHARMACEUTICALS, INC. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 257937 · SEC code covers open-market or private transactions · Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. · The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. · Chief Commercial & Medical Affairs Officer | 2026-11-09 | 2026-11-12 | ≈ $11,337.14 4,872 shares/units | SEC 4 | Follow |
| Wilson Martin General Counsel · ROCKET PHARMACEUTICALS, INC. | RCKT ROCKET PHARMACEUTICALS, INC. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 545100 · SEC code covers open-market or private transactions · Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. · The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. | 2026-11-05 | 2026-11-09 | ≈ $127,813.27 53,389 shares/units | SEC 4 | Follow |
Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.